Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02406742 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT02406742 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 47 participants.
The verdict
NCT02406742, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
Safety, pharmacokinetics, and preliminary efficacy of CC-122 alone and in combination with ibrutinib and obinuzutumab. CC-122 has multiple activities, including immune modulation of several immune cell subsets and antiproliferative activity in CLL. CC-122 has also been shown to have a tolerable safety profile with some preliminary signs of efficacy with early human experience.
Interventions
- DRUG Obinutuzumab
- DRUG Ibrutinib
- DRUG CC-122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-07-27 |
| Est. Completion | 2020-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02406742
The ClinicalTrials.gov registry entry for NCT02406742 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT02406742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02406742 about?
NCT02406742 is a clinical study titled "A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". Safety, pharmacokinetics, and preliminary efficacy of CC-122 alone and in combination with ibrutinib and obinuzutumab. CC-122 has multiple activities, including immune modulation of several immune cell subsets and antiproliferative activity in CLL. CC-122 has also been shown to have a tolerable saf...
What is the current status of trial NCT02406742?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2015-07-27. Estimated completion is 2020-07-07.
What interventions are being tested in trial NCT02406742?
The interventions under investigation include: Obinutuzumab (DRUG), Ibrutinib (DRUG), CC-122 (DRUG).
Who is sponsoring clinical trial NCT02406742?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.